Sr. Director, Early Phase Chemistry at Eli Lilly and Company

Indianapolis, Indiana, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceutical, BiotechnologyIndustries

Requirements

Veteran and visionary leader in drug substance development
Expertise in shaping the direction of early phase chemistry initiatives
Experience building and leading a world-class team in synthetic chemistry
Ability to develop internal synthetic capabilities and oversee external programs at CDMOs
Strategic guidance in synthetic, formulation, and manufacturing strategies, including integration of new technologies
Experience driving synthetic route selection and route scouting from Discovery to Ph II, internally and at partner CDMOs
Ability to communicate complex technical concepts

Responsibilities

Create a high-performance team culture with clarity of roles, responsibilities, and expectations
Ensure safety of employees and facilities with robust safety programs and procedures
Recruit, develop, and grow the next generation of leaders
Actively coach and mentor scientists of all levels across the organization
Foster an environment of collaboration and innovation within the early phase chemistry group and larger Lilly Research Labs organization
Deliver Early Phase material to meet toxicologic and clinical milestones
Develop a global network of active pharmaceutical ingredient, starting materials, and custom intermediates at CDMOs
Build and drive the strategy for internal Small Molecules efforts at the Medicine Foundry
Provide strategic guidance including synthetic, formulation, and manufacturing strategies; integrate and apply new technologies
Partner with cross-functional teams to ensure seamless integration of CMC development activities with discovery, toxicology, and clinical development
Accelerate discovery and development learnings through Lilly Research Labs partnership from pre-candidate selection to clinical supply material generation
Integrate new technology and partnerships to increase Early Phase capabilities and efficiencies
Drive successful synthetic route selection and route scouting efforts from Discovery to Ph II, internally and at partner CDMOs

Skills

Organic Chemistry

Synthetic Chemistry

Drug Substance Development

Process Development

Small Molecules

Peptides

Oligonucleotides

Leadership

Regulatory Affairs

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free